References

1. Dighiero G, Travade P, Chevret S et al: The French Cooperative Group on CLL. B-cell chronic lymphocytic leukemia: Present status and future directions. Blood 78:1901-1914, 1991.

2. O'Brien S, delGiglio A, Keating M: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 85:307-318, 1995.

3. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052-1057, 1995.

4. Hoyer JD, Ross CW, Li C-Y et al: True T-cell chronic lymphocytic leukemia: A morphologic and immunophenotypic study of 25 cases. Blood 86:1163-1169, 1996.

5. Barliner NT: Gamma lymphocytosis and T cell chronic leukemias. Hematol Oncol Clin North Am 4:473-487, 1990.

6. Haenszel W, Kurihara M: Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 40:43-68, 1968.

Yanagihara ET, Blaisdell RK, Hayashi T, Lukes RJ: Malignant lymphoma in Hawaii-Japanese: A retrospective morphologic survey. Hematol Oncol 7:219-232, 1989.

Preston DL, Kusumi S, Tomonoga M et al: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma. Radiat Res 137 (Suppl 2):S68-97, 1994. Arp EW, Wolf PH, Checkoway H: Lymphocytic leukemia and exposure to benzene and other solvents in the rubber industry. J Occup Med 25:598-602, 1983.

Blair A, White D: Leukemia cell types and agricultural practices in Nebraska. Arch Environ Health 40:211-214, 1985. Brandt L: Environmental factors and leukemia. Med Oncol Tumor Pharmacother 2:7-10, 1985.

Conley CL et al: Genetic factors predisposing to chronic lymphocytic leukemia and autoimmune disease. Medicine (Baltimore) 5:323-334, 1980.

Gunz FW et al: Familial leukemia: A study of 909 families. Scand J Haematol 15:117-131, 1975.

Linet MS et al: Familial cancer history and chronic lymphocytic leukemia. Am J Epidemiol 130:655-664, 1989. Landis SH, Murray T, Bolden S, Wingo PA: Cancer Statistics 2000: CA Cancer J Clin 50:7, 2000.

Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1999. CA Cancer J Clin 49:8-31, 1999.

Fleming AF: The epidemiology of lymphomas and leukemias in Africa: An overview. Leuk Res 9:735-740, 1985. Caligaris-Cappio F: B-chronic lymphocytic leukemia: A malignancy of anti-self B cells. Blood 87:2615-2620, 1996. Kipps TJ, Carson DA: Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune disease. Blood 81:2475-2487, 1993.

International Workshop on Chronic Lymphocytic Leukemia: Chronic lymphocytic leukemia: Recommendations for diagnosis, staging and response criteria. Ann Intern Med 110:236-238,1989. Cheson BD, Bennett JM, Grever M et al: National Cancer Institute-sponsored Working Group guidelines for chronic lympho-cytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996.

Gray JL et al: Bone marrow and peripheral blood lymphocytosis in the prognosis of chronic lymphocytic leukemia. Cancer 33:1169-1178, 1974.

Bennett JM, Catovsky D, Daniel MT et al: Proposals for the classification of chronic (mature) B and T lymphoid leukemias. J Clin Pathol 42:567-584, 1989.

Lipshutz MD, Mir R, Rai KR, Sawitsky A: Bone marrow biopsy and clinical staging in chronic lymphocytic leukemia. Cancer 46:1422-1427, 1980.

Pangalis GA, Boussiotis VA, Kittas C: B chronic lymphocytic leukemia. Disease progression in 150 untreated stage A and B patients as predicted by bone marrow pattern. Nouv Rev Fr Hematol 30:373-375, 1988.

Rozman C, Montserrat E, Rodriquez-Fernandez JM et al: Bone marrow histologic pattern, the best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases. Blood 64:642-648, 1984.

Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, Siakantaris MP, Kittas C: B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders. Semin Hematol 36:104-114, 1999.

De Rossi G, Granati L, Girelli G et al: Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 30:403-406, 1988.

29. Rustagi P et al: Antigranulocyte antibodies in CLL and other chronic lymphoproliferative disorders. Blood 62(Suppl. 1):106, 1983.

30. Giardina SL et al: The generation of monoclonal anti-idiotypic antibodies to human B-cell derived leukemias and lymphomas. J Immunol 135:653-658, 1985.

31. Oscier D, Fitchett M, Herbert T, Lambert R: Karyotypic evolution in B-cell chronic lymphocytic leukemia. Genes Chromosom Cancer 3:16-20, 1991.

32. Beaume A, Brizard A, Dreyfus B et al: High incidence of serum monoclonal Igs detected by a sensitive immunoblotting technique in B-cell lymphocytic leukemia: Blood 84:1216-1219, 1994.

33. Deegan MT et al: High incidence of monoclonal proteins in the serum and urine of chronic lymphocytic leukemia patients. Blood 64:1207-1211, 1984.

34. Qian GX et al: Circulating monoclonal IgM proteins in B cell chronic lymphocytic leukemia. J Immunol 133:3396-3400, 1984.

35. Geisler CH, Larsen JK, Hansen NE et al: Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. Blood 78:1795-1802, 1991.

36. Harris NL, Jaffe ES, Stein H et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

37. Ikematsu W, Ikematsu H, Okamura S et al: Surface phenotype and Ig heavy-chain gene usage in chronic B-cell leukemias: Expression of myelomonocytic surface markers in CD5-chronic B-cell leukemia. Blood 83:2602-2610,1994.

38. Rechavi G et al: Immunoglobulin heavy chain rearrangements in chronic lymphocytic leukemia: Correlation with clinical stage. Br J Haematol 72:524-529, 1989.

39. Perl A et al: Rearrangement of the T-cell receptor alpha, beta and gamma chain genes in chronic lymphocytic leukemia. Leuk Res 14:131-137, 1990.

40. Norton JD et al: Rearrangement and expression of T cell antigen receptor genes in B cell chronic lymphocytic leukemia. Blood 71:178-185, 1988.

41. Kay NE: Abnormal T cell subpopulation function in CLL: Excessive suppressor and deficient helper activity with respect to B cell proliferation. Blood 57:418-420, 1981.

42. Platsoucas CD et al: Abnormal T lymphocyte subpopulations in patients with B cell CLL. J Immunol 129:2305-2312, 1982.

43. Catovsky D et al: Increase in T lymphocytes in B-cell CLL. Br J Haematol 47:539-544, 1981.

44. Rossi JF et al: Production of B-cell growth factor interleukin 2 and gamma interferon by peripheral blood lymphocytes from patients with chronic lymphocytic leukemia of B cell type. Am J Hematol 29:183-188, 1988.

45. Han T, Dadly B: In vitro functional studies of mononuclear cells in patients with CLL. Cancer 43:109-117, 1979.

46. Han T et al: Lack of autologous mixed lymphocyte reaction in patients with CLL. Blood 60:1075-1081, 1982.

47. Lauria F et al: T cell functional abnormality in B-CLL: Evidence of a defect of the T helper subset. Br J Haematol 54:277-283, 1983.

48. Ziegler HW et al: Deficiency of natural killer cell activity in patients with CLL. Int J Cancer 27:321-327, 1981.

49. Burton JD et al: Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down regulate T cell and NK function. Am J Hematol 30:61-67, 1989.

50. Kay NE, Perri RT: Evidence that large granular lymphocytes from B-CLL patients downregulate B cell immunoglobulin synthesis. Blood 73:1016-1019, 1989.

51. Pritsch O, Maloum K, Dighiero G: Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 25:34-41, 1998.

52. Diehl LF, Ketchum LH: Autoimmune disease and chronic lym-phocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 24:80-97, 1998.

53. Hamblin TJ, Oscier DJ, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39:713-716, 1986.

54. DiRaimondo F, Giustolisi R, Cacciola E et al: Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma 11:63-68, 1993.

55. Myint H, Copplestone JA, Orchard J et al: Fludarabine-related autoimmune hemolytic anemia in patients with chronic lympho-cytic leukemia. Br J Haematol 91:342-344, 1995.

56. Rai KR, Sawitsky A, Cronkite EP et al: Clinical staging of chronic lymphocytic leukaemia. Blood 46:219-234, 1975.

57. Dameshek W: Chronic lymphocytic leukemia: An accumulative disease of immunologically incompetent lymphocytes. Blood 29:566-584, 1967.

58. Rai KR: A critical analysis of staging in CLL. In Gale RP, Rai KR (eds): Chronic Lymphocytic Leukemia: Recent Progress and Future Direction. UCLA Symposia on Molecular and Cellular Biology, New Series, Vol.59, p. 253. Liss, New York, 1987.

59. Binet J-L, Auquier A, Dighiero G et al: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198-206,1981.

60. Rai KR, Montserrat E: Prognostic factors in chronic lymphocytic leukemia. Semin Hematol 24:252-256, 1987.

61. Zwiebel JA, Cheson BD: Chronic lymphocytic leukemia: Staging and prognostic factors. Semin Oncol 25:42-59, 1998.

62. Montserrat E et al: Lymphocyte doubling time in chronic lym-phocytic leukaemia. Analysis of its prognostic significance. Br J Haematol 62:567-575, 1986.

63. Geisler C, Philip P, Hansen M: B-cell chronic lymphocytic leukemia: Clonal chromosome abnormalities and prognosis in 89 cases. Eur J Haematol 43:397-403, 1989.

64. Oscier DG, Stevens H, Hamblin TJ et al: Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukaemia. Br J Haematol 76:352-358, 1990.

65. Juliusson G, Oscier DG, Fitchett M et al: Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosome abnormalities. N Engl J Med 323:720-724, 1990.

66. Han T, Henderson ES, Emrich LJ, Sandberg AA: Prognostic significance of karyotypic abnormalities in B-cell chronic lympho-cytic leukemia: An update. Semin Hematol 24:257-263, 1987.

67. Di Giovanni S, Valentini G, Carducci P, Giallonardo P: Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia. Acta Haematol 81:181-185, 1989.

68. Keating MJ, Lerner S, Kantarjian H et al: The serum beta 2-microglobulin (beta2M) level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL). 86:606a, 1995.

69. Sarfati M, Chevret S, Chastang C et al: Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 88:4259-4264, 1996.

70. Knauf WU, Langenmayer I, Ehlers B et al: Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia. Leuk Lymphoma 27:523-532, 1997.

71. Vallespi T et al: Chronic lymphocytic leukaemia: Prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br J Haematol 77:478-485, 1991.

72. Peterson L et al: Morphology of chronic lymphocytic leukemia and its relationship to survival. Am J Med 59:316-324, 1975.

73. Damle RN, Wasil T, Fais F et al: IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999.

74. Naylor M, Capra JD: Mutational status of Ig VH genes provide clinically valuable information in B-cell chronic lymphocytic leukemia. Blood 94:1837-1839, 1999.

75. Montserrat E, Rozman C: Chronic lymphocytic leukemia: Prognostic factors and natural history. Bailliere Clin Hematol 6:849-866, 1993.

76. Dighiero G, Maloum K, Desablens B et al: Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338:1506-1514, 1998.

77. Cheson BD, Bennett JM, Rai KR et al: Guidelines for clinical protocols for chronic lymphocytic leukemia (CLL). Recommendations of the NCI-sponsored Working Group. Am J Hematol 29:152-163, 1988.

78. Cheson BC, Bennett JM, Grever M et al: National Cancer Institute-sponsored Working Group guidelines for chronic lympho-cytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1998.

79. Colvin M: A review of the pharmacology and clinical use of cyclophosphamide. In Pinedo HM (ed.): Clinical Pharmacology of Antineoplastic Drugs, p. 245. Elsevier-North Holland, Amsterdam, Netherlands.

80. Ezdinli EZ, Stutzman L: Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA 191:444, 1965.

81. Knospe WH, Loeb V Jr, Huguley CM Jr: Bi-weekly chlorambucil treatment of chronic lymphocytic leukemia. Cancer 33:555-562, 1974.

82. Ezdinli EZ, Stutzman L, W. Aungst C et al: Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer 23:900-909, 1969.

83. Galton DAG, Wiltshaw E, Szur L, et al: The use of chlorambucil and steroids in the treatment of chronic lymphocytic leukaemia. Br J Haematol 7:73, 1961.

84. Han T et al: Chlorambucil vs combined chlorambucil-corticos-teroid therapy in chronic lymphocytic leukemia. Cancer 31:502-508, 1973.

85. Sawitsky A, Rai KR, Glidewell O, Silver RT, and participating members of CALGB (Cancer and Leukemia Group B): Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood 50:1049-1059, 1977.

86. Jaksic B, Brugiatelli M: High-dose continuous chlorambucil vs intermittent chlorambucil plus prednisone for treatment of B-CLL. IGCI CLL-01 trial. Nouv Rev Fr Hematol 30:437-442, 1988.

87. Liepman M, Votaw ML: Treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 41:1664-1669, 1978.

88. Oken MM, Kaplan ME: Combination chemotherapy with cyclophosphamide, vincristine and prednisone in the treatment of refractory CLL. Cancer Treat Rep 63:441-447, 1979.

89. French Cooperative Group on Chronic Lymphocytic Leukemia: A randomized clinical trial of chlorambucil versus COP in Binet stage B chronic lymphocytic leukemia. Blood 75:1422-1425, 1990.

90. Raphael B, Andersen JW, Silber R et al: Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: Long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. J Clin Oncol 9:770-776, 1991.

91. French Cooperative Group on Chronic Lymphocytic Leukemia: Long-term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br J Haematol 73:334-340, 1989.

92. Jaksic B, Brugiatelli M, Krc I, et al: High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: Results of an international multicentric randomized trial. Cancer 79:2107-2114, 1997.

93. Grever MR, Kopecky KJ, Coltman CA et al: Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457-459, 1988.

94. Keating MJ, Kantarjian H, Talpaz M et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989.

95. O'Brien S, Kantarjian H, Beran M et al: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 82:1695-1700, 1993.

96. Cheson B: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13:2431-2448, 1995.

97. Puccio CA, Mittelman A, Lichtman SM et al: A loading dose continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9:1562-1569, 1991.

98. Robertson LE, O'Brien S, Kantarjian H et al: A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia 9:1444-1449, 1995.

99. Keating MJ, Kantarjian H, O'Brien S et al: Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9:44-49, 1991.

100. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD: 2-Chlorodeoxyadenosine treatment of refractory chronic lympho-cytic leukemia. Leuk Lymphoma 5:133-138, 1991.

101. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 11:679-689,1993.

102. Robak T, Blasinka-Morawiec M, Krykowski E et al: Intermittent 2hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 22:509-514,1996.

103. Saven A, Lemon RH, Kasty M et al: 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 13:570-575, 1995.

104. Juliusson G, Elmhorn-Rosenborg A, Liliemark J: Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lympho-cytic leukemia resistant to fludarabine. N Engl J Med 327:1056-1061, 1992.

105. O'Brien S, Kantarjian H, Estey E et al: Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lympho-cytic leukemia refractory to fludarabine therapy. N Engl J Med 330:319-322, 1994.

106. Dillman RO, Mick R, McIntyre OR: Pentostatin in chronic lym-phocytic leukemia: A phase II trial of Cancer and Leukemia Group B. J Clin Oncol 7:433-438, 1989.

107. Ho AD, Thaler J, Stryckmans P et al: Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European Organization for Research and Treatment of Cancer. J Natl Cancer Inst 82:1416-1420, 1990.

108. Johnson SA, Catovsky D, Child JA, Newland AC, Milligan DW, Janmohamed R: Phase I/II evaluation of Pentostatin (2'-deoxyco-formycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia. Invest New Drugs 16:155-160, 1998.

109. The French Cooperative Group on CLL, Johnson S, Smith AG, Löf-fler H et al: Multicenter prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. Lancet 347:1432-1438,1996.

110. Rai KR, Peterson B, Elias I et al: A randomized comparison of flu-darabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia: A CALGB, SWOG, CTG/NCI-C and ECOG Intergroup Study. N Engl J Med. 343:1750-1757,2000.

111. Robak T, Blonski JZ, Kasznicki M et al: Cladribine with pred-nisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood 96:2723-2729, 2000.

112. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M et al: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171, 1998.

113. Thomas D, O'Brien S, Kantarjian H, Giles FJ, Lerner S, Keating MJ: Outcome in 203 patients (pts) with relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) with salvage therapy (RX): Retreatment with fludarabine (FLU). Blood 92(Suppl. 1):102a (abstr. 419), 1998.

114. Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M et al: Treatment of alkylator resistant chronic lymphocytic leukemia with oral flu-darabine phosphate. Blood 11(4):abstr #3113, 1999.

115. Robertson LE, Hu Y, Butler JJ et al: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, pathologic, immunophenotypic, and molecular analysis. Blood 80:29-36, 1992.

116. Bellosillo B, Villamor N, Colomer D, Montserrat E et al: In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 94:2836-2843, 1999.

117. Koehl L, Nowak B, Van Haperen R, Kornhuber B et al: Synergistic cytotoxicity using cyclophosphamide and nucleoside analogs. In Hiddeman W, Buechner T, Wormann B, Ritter J, Creutzig U, Keating MJ, and Plunkett W (eds): Acute Leukemias VII: Experimental Approaches and Novel Therapies, pp. 549-555. Springer-Verlag, Berlin, 1997.

118. Flinn IW, Byrd JC, Morrison C, Jamison J et al: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 96:71-75, 2000.

119. O'Brien S, Kantarjian HM, Cortes J, Beran M et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001.

120. Zeigler-Heitbrock HWL, Schlag R, Flieger D, Thiel E: Favorable response of early stage B-CLL patients to treatment with IFN-a2. Blood 73:1426-1430, 1989.

121. McSweeney EN, Giles FJ, Worman CP et al: Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukemia. Br J Haematol 85:77-83, 1993.

122. Foon KA, Bottino GC, Abrams PG et al: Phase II trial of recombinant leukocyte A interferon in patients with advanced chronic lymphocytic leukemia. Am J Med 78:216-220, 1985.

123. Montserrat E, Villamor N, Urbrano-Ispizua A et al: Treatment of early stage-B chronic lymphocytic leukemia with alpha-2B inter-

feron after chlorambucil reduction of the tumoral mass. Ann Hematol 63:15-19, 1991.

124. O'Brien S, Kantarjian H, Beran M et al: Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood 86:1296-1300, 1995.

125. Zinzani PL, Bendandi M, Magagnoli M, Rondelli D et al: Results of a fludarabine induction and a-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Eur J Haematol 59:82-88, 1997.

126. McLaughlin P, Grillo-Lopez J, Link BK et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998.

127. Winkler U, Jenson M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lympho-cytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217-2224, 1999.

128. Byrd JC, Murphy T, Lucas MS, Howard R et al: Thrice weekly Rituximab demonstrates significant activity in chronic lymphocytic leukemia. Blood 96:abstr. #3615, 2000.

129. O'Brien S, Kantarjan H. Thomas DA et al: Rituximab dose-escalation trial in chronic lymphocytic leukemia (CLL). J Clin Oncol 19(8):2165-2170, 2001.

130. Keating MJ, O'Brien S, Lerner S, Giles F et al: Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and Rituximab achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL). Blood 96:abstr. #2214.

131. Riechmann L, Clark M, Waedmann H et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988.

132. Osterborg A, Dyer MJS, Bunjes D, Pangalis GA et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567-1574, 1997.

133. Rai K, Mercier RJ, Cooper MR, Freter CB et al: Campath-1H is an effective salvage therapy for fludarabine failing CLL patients, results of a Phase II trial. Blood 96:abstr. #703.

134. Keating M, Rai K, Flinn I et al: Multicenter study of Campath-IH in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood 94(10):75a, 1999.

135. Michallet M, Archimbaud E, Bandini G et al: HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124:311-315, 1996.

136. Rabinowe SN, Soiffer RJ, Gribben JG et al: Autologous and allo-geneic bone marrow transplant for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 82:1366-1376, 1993.

137. Khouri IF, Keating MJ, Vriesendorp H et al: Autologous and allo-geneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results. J Clin Oncol 12:748-758, 1994.

138. Sutton L, Malourn K, Gonzalez H, Zouabi H et al: Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 12:1699-1707, 1998.

139. Khouri IF, Keating M, Korbling M et al: Transplant-Lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16,2817, 1998.

140. Mauro FR, Foa R, Giannarelli D et al: Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: A single institution study of 204 cases. Blood 94:448-454, 1999.

141. Delpero JR, Houvenaeghel G, Gastaut JA et al: Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-Hodgkin's lymphomas. Br J Surg 77:443, 1990.

142. Ferrant A, Michaux JL, Sokal G: Splenectomy in advanced chronic lymphocytic leukemia. Cancer 58:2130, 1986.

143. Stein RS, Weikert D, Reynolds V et al: Splenectomy for end-stage chronic lymphocytic leukemia. Cancer 59:1815, 1987.

144. Thiruvengadam R, Piedmonte M, Barcos M et al: Splenectomy in advanced chronic lymphocytic leukemia. Leukemia 4:758, 1990.

145. Pegourie B, Sotto J, Hollard D et al: Splenectomy during chronic lymphocytic leukemia. Cancer 59:1626, 1987.

146. Gallhofer G, Melo JV, Spencer J, Catovsky D: Splenectomy in advanced chronic lymphocytic leukaemia. Acta Haematol 77:78, 1987.

147. Majumdar G, Singh AK: Role of splenectomy in chronic lymphocytic leukaemia with massive splenomegaly and cytopenia. Leuk Lymphoma 7:131, 1992.

148. Neal TF Jr, Tefferi A, Witzig TE et al: Splenectomy in advanced chronic lymphocytic leukemia: A single institution experience with 50 patients. Am J Med 93:435-440, 1992.

149. Seymour JF, Cusack JD, Lerner SA et al: Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol 15:52-60, 1997.

150. Byhardt RW, Brace KC, Wiernik PH: The role of splenic irradiation in chronic lymphocytic leukemia. Cancer 35:1621-1625, 1975.

151. Guiney MJ, Liew KH, Quong GG et al: A study of splenic irradiation in chronic lymphocytic leukemia. Int J Radiat Oncol Biol Phys 16:225-229, 1989.

152. De Rossi G, Biagini C, Lopez M et al: Treatment by splenic irradiation in 22 chronic lymphocytic leukemia patients. Tumori 68:511-514, 1982.

153. Johnson RE: Role of radiation therapy in management of adult leukemia. Cancer 39:852-855, 1977.

154. Johnson RE, Kagan AR, Gralnick HR et al: Radiation-induced remissions in chronic lymphocytic leukemia. Cancer 20:1382-1387, 1967.

155. Aabo K, Walbom-Jorgensen S: Spleen irradiation in chronic lym-phocytic leukemia (CLL): Palliation in patients unfit for splenectomy. Am J Hematol 19, 177-180, 1985.

156. Roncadin M, Arcicasa M, Trovo MG et al: Splenic irradiation in chronic lymphocytic leukemia. A 10-year experience at a single institution. Cancer 60:2624-2628, 1987.

157. Chisesi T, Capnist G, Dal Fior S: Splenic irradiation in chronic lymphocytic leukemia. Eur J Haematol 46:202-204, 1991.

158. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 39:713, 1986.

159. Chikkappa G, Zarrabi MH, Tsan MF: Pure red-cell aplasia in patients with chronic lymphocytic leukaemia. Medicine (Baltimore) 65:339, 1986.

160. Singal R, Winfield DA, Greaves M: Bone marrow aplasia in B cell chronic lymphocytic leukemia: Successful treatment with antithy-mocyte globulin. J Clin Pathol 44:954, 1991.

161. De Rossi G, Granati L, Girelli G et al: Incidence and prognostic significance of autoantibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 30:403, 1998.

162. De Rossi G, Granati L, Girelli G et al: Prognostic value of autoan-tibodies against erythrocytes and platelets in chronic lymphocytic leukemia (CLL). Tumori 77:100, 1991.

163. Tura S, Finelli C, Bandini G et al: Cyclosporin A in the treatment of CLL associated PRCA and bone marrow hypoplasia. Nouv Rev Fr Hematol 30:479, 1988.

164. Cortes J, O'Brien S, Kantarjian H, Giles FJ, Keating M: Treatment of anemia and/or thrombocytopenia associated with chronic lymphocytic leukemia with cyclosporin A. Blood 92(Suppl 1):104a (abstr. #425), 1998.

165. Foon KA, Gale RP: Clinical transformation of chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:385, 1988.

166. Giles FJ, O'Brien S, Keating M: Chronic lymphocytic leukemia in (Richter's) transformation. Semin Oncol 25:117-125, 1998.

167. Robertson LE, Pugh W, O'Brien S et al: Richter's syndrome: A report on 39 patients. J Clin Oncol 11:1985, 1993.

168. Foucar K, Rydell RE: Richter's syndrome in chronic lymphocytic leukemia. Cancer 46:118, 1990.

169. Long JC, Aisenberg AC: Richter's syndrome. A terminal complication of chronic lymphocytic leukemia with distinct clinicopatho-logic features. Am J Clin Pathol 63:766, 1975.

170. Armitage JO, Dick FR, Corder MP: Diffuse histocytic lymphoma complicating chronic lymphocytic leukemia. Cancer 41:422, 1978.

171. Trump DL, Mann RB, Phelps R et al: Richter's syndrome: Diffuse histiocytic lymphoma in patients with chronic lymphocytic leukemia. Am J Med 68:539, 1980.

172. Zarrabi M, Grunwald HW, Rosner F: Chronic lymphocytic leukemia terminating in acute leukemia. Arch Intern Med 137:1059, 1977.

173. Litz CE, Arthur DC, Gajl-Peczalska KJ et al: Transformation of chronic lymphocytic leukemia to small non-cleaved cell lymphoma: A cytogenetic, immunological, and molecular study. Leukemia 5:972, 1991.

174. Pistoia V, Roncella S, Di Celle PF et al: Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lympho-cytic leukemia: Evidence for the single-cell origin of the two tumors. Blood 78:797, 1991.

175. Duchayne E, Delsol G, Kuhlein E et al: Hairy cell transformation of a B-cell chronic lymphocytic leukemia: A morphological, cyto-chemical phenotypic and molecular study. Leukemia 5:150, 1991.

176. Fayad L, Robertson LE, O'Brien S, Manning JT et al: Hodgkin's disease variant of Richter's syndrome: Experience at a single institution. Leuk Lymphoma 23:333-337, 1996.

177. Berg JW: The incidence of multiple primary cancers. 1. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst 38:741, 1967.

178. Pottern LM, Linet M, Blair A et al: Familial cancers associated with subtypes of leukemia and non-Hodgkin's lymphoma. Leuk Res 15:305, 1991.

179. Travis LB, Curtis RE, Hankey BF et al: Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst 84:1422, 1992.

180. Lee JS, Dixon DO, Kantarjian HM et al: Prognosis of chronic lym-phocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 69:929, 1987.

181. Cheson BD, Vena DA, Barrett J, Freidlin B: Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454, 1999.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment